The spike is real, and it’s big too. Revenues increased from $4.8 million during the fiscal year to December 2023, to $71.5 million during FY2024, and $74.1 million during FY2025. This is over fifteen times in two years. Not many publicly listed firms have a chart looking like this. But this type of a chart should rather increase the readers’ caution because such an incredible rate of growth rarely happens due to a lot of clients. Instead, it happened due to only one.

From a Shanghai supply-chain desk to an SGX listing

The company that will trade on the SGX Mainboard was incorporated in Singapore only on 24 December 2021, and became a public company as recently as 19 June 2026. It was set up as a joint venture between AGX Singapore, a subsidiary of the Bursa-listed logistics group AGX Group Berhad, and Mr. Xu Hao, a Chinese logistics entrepreneur. Mr. Xu Hao does not sit on the board. His wife does. Mdm. Tang Ying, formerly a vice-president at a Shanghai supply-chain company, is an Executive Director and, before the offering, the 70% controlling shareholder. AGX Singapore holds the other 30%.

The name came with the relationship. As per the prospectus, the name chosen by the company on incorporation was meant to indicate its origin and commercial relationship with All-Link PRC, a different Chinese-owned freight forwarding firm which Mr. Xu Hao owns through his 64.8% ownership and which the document is very careful to point out does not belong to the group to be listed. There are also at least two other firms trading under related names. Since then, All-Link has established its own customer base using the trade name, its own logo, and even filed an application for trademark registration of the name in Malaysia – the application remains pending – in the name of its Malaysian subsidiary rather than the company that is to be listed. Bear the relationship in mind, because it is the entire thesis. The listed company was incorporated to provide logistical services to the customers of All-Link PRC, moving the cargo of these customers into Southeast Asia and earning its money from doing so.

The operating history is short. Singapore operations began in 2022. A Philippines subsidiary was incorporated in September 2022. In 2024 the group was appointed a logistics provider to the TikTok Group. In 2025 it incorporated a Malaysian arm and, in August, bought the freight-forwarding business of a local operator called MF Logistics, which is the source of the only goodwill on its balance sheet. Headcount went from ten to seventy in about a year, and had reached 112 by the time the final prospectus was registered. This is a company that grew up around a single opportunity, very fast, and is now asking for permanent public capital on the strength of it.

What the offer actually contains

All-Link is selling 37,924,500 new shares at S$0.53 each, split into a 35,824,500-share placement and a small 2,100,000-share public tranche. The public offer opened on 28 July and closes at noon on 3 August, with trading expected to start on the Mainboard at 9.00 a.m. on 5 August 2026. Every share on offer is newly issued, so the money raised goes to the company rather than to the sellers, and the raise is sponsored, underwritten and placed by CGS International Securities Singapore. The prospectus expressly grants no over-allotment option, and discloses no cornerstone investor or tranche, which for a deal this size is worth noting rather than assuming.

At S$0.53, the 151,037,900 shares in issue after the offering value the whole company at about S$80 million. The offering represents 25.1% of that, so roughly three-quarters of the company stays with the people who already own it: Mdm. Tang Ying with 51.7% and AGX Singapore, and behind it the Bursa-listed AGX Group Berhad, with 23.2%. The public float is 25.1%, but the portion actually offered to retail investors through the public tranche is only 2.1 million shares, about 1.4% of the company. This is a placement-led listing with a thin retail slice, and the controllers keep firm control.

The proceeds, roughly S$17.7 million after expenses, are earmarked for expansion, for “strategic acquisitions” (part of which is intended to buy out Mr. Xu Hao’s 30% stake in a related Vietnamese operation), for technology, and for working capital to pay airlines and carriers. None of it goes to repaying debt, because there is essentially none.

One item in the offer deserves to be read slowly. In March and June 2026, in the months before the listing, the company declared a US$8.0 million dividend in respect of FY2025, split as a US$2.0 million interim and a US$6.0 million final payment. Roughly US$5.6 million of that flows to Mdm. Tang Ying and US$2.4 million to AGX Singapore. That US$8.0 million is about S$10.3 million, or close to 13% of the entire post-listing market value, paid out to the controllers on the way in. On a pro forma basis it cuts the group's cash from US$23.6 million to US$15.6 million and its net assets from US$16.2 million to US$8.2 million. New shareholders do not share in it. They are buying the company the morning after the payout, then supplying fresh capital of their own on top.

The revenue that is not quite the company’s own

The single most important disclosure in the prospectus is not a number in the accounts. It is the sentence that says roughly 90% to 99.9% of the group’s revenue over the three years came from customers referred by All-Link PRC. In FY2023 and FY2024 the figure was above 99%. In FY2025 it was 90.4%.

This is important since All-Link PRC is not the customer that has an agreement and a purchase order. This is the family-run Chinese firm that provides the listed firm with the orders. The agreement between the two is now under the Non-Compete and Collaboration Deed of 30 June 2026 where All-Link PRC promises to give priority to the group when shipping to ASEAN countries. However, the risk factors of the group itself are rather blunt about the fragile nature of this protection. The deed is terminable and it automatically terminates if the firm is delisted or if Mrs. Tang Ying and Mr. Xu Hao lose control of the firm. Beyond this, as stated in the prospectus, All-Link PRC may reduce, redirect or stop the referrals “without liability to our Group”. In other words, the source of almost all the revenues lies with a firm that is run by the controlling shareholder’s husband, and continues to function due to the family retaining control and not due to any commercial obligation.

The dependency runs the other way too. To service that referred business, the group buys freight-forwarding and related services back from All-Link PRC, about US$20.5 million worth in FY2025, a sum equal to roughly 139% of the group’s latest net tangible assets, for origin-side handling in China where the listed company has no operating presence. So the referrer is also a major supplier, accounting for 31.5% of last year’s cost of sales. Money flows to the family entity on both sides of the trade.

The cost side concentrates too, and around the same name. The group’s largest supplier, at 40.5% of last year’s cost of sales and 79.7% the year before, is a company called All-Link Air and Sea Company Limited, which the prospectus says is not part of the group and is managed independently. The document does not define it, does not say what country it is registered in, and does not name its owners, though it does state that no director or substantial shareholder holds an interest in any major supplier apart from Mr. Xu Hao’s stake in All-Link PRC. Between them, two separately managed businesses carrying the All-Link name supplied 72% of last year’s costs.

Who this company answers to

Ownership answers part of the question the offer poses. After listing, Mdm. Tang Ying holds 51.7% and AGX Singapore 23.2%, so roughly three-quarters of the company stays with the insiders, and the 25.1% float, most of it placed rather than offered to the public, carries little voting weight. A minority buying in here is a genuine minority.

The more unusual feature is who sits behind AGX Singapore. It is wholly owned by AGX Group Berhad, which is itself a listed company, on the ACE Market of Bursa Malaysia. The prospectus is explicit about what that parent does:

“AGX Group Berhad is a company listed on the ACE Market of Bursa Malaysia and is principally in the business of providing sea and air freight forwarding, aerospace logistics, warehousing, road transport and distribution services globally. Save for aerospace logistics, the AGX Group operates in substantially similar business segments as our Group in overlapping geographical markets, including Singapore, Malaysia and the Philippines.”

In plain terms, one of All-Link’s controlling shareholders is also a listed competitor. That is the company’s own disclosure, not our characterisation. The alignment of the people running it points the same way. Mr. Peter Neo, the chief executive, owns no All-Link shares at all; his 18.90% economic stake is in AGX, the competitor he co-founded and whose board he left only on 1 January 2026. Mr. Chang Poh Sheng sits on All-Link’s board while serving as chief financial officer of AGX and holding 2.36% of it. The hands on the wheel still have meaningful ties next door.

That overlap is managed by agreement rather than by competition. On 30 June 2026 the two companies undertook not to solicit each other’s ten largest customers, and the All-Link names covered by that pact accounted for 100%, 100% and 94.7% of the group’s revenue across FY2023 to FY2025. Almost the entire customer book, in other words, is fenced off from the parent by a private undertaking, and like the referral deed it lasts only while AGX stays in control and the company stays listed. Half of the six-person board is independent, which is the regulatory minimum rather than a comfort, and the controlling shareholders’ lock-ups run just six months. What a buyer is being offered is a quarter of a company controlled by a listed rival, fed by a private family entity, with its customers allocated by contract rather than won in the open market.

The financial scoreboard

Look past the revenue line and the picture is not one of a business getting stronger. Gross margin fell from 40.4% in FY2023, when the company was tiny, to 14.7% in FY2024 and 12.0% in FY2025. Profit attributable to owners, the figure that matters to a shareholder, fell 25% in FY2025 even as revenue edged higher, from US$8.4 million to US$6.3 million. Administrative expenses nearly tripled to US$1.8 million as the company built out and prepared to list. And roughly US$0.8 million of the US$7.9 million pre-tax profit was simply interest earned on the cash pile, much of which is now being paid out as the pre-IPO dividend.

Cash flow tells the sharpest version of the story. Operating cash flow was positive US$29.9 million in FY2024, then turned to negative US$8.0 million in FY2025, as a large swing in trade payables unwound. For a business with almost no fixed assets, working capital is the whole game, and in its most recent year the working-capital tide went out.

The loophole that closed

To understand why the economics turned, you have to understand what the TikTok cargo was. It was low-value e-commerce parcels moving by air from China to the United States, the same flow that powered the rise of Shein, Temu and TikTok Shop. That flow existed on the scale it did because of the United States de minimis exemption, which let goods worth under US$800 enter the country free of duties and taxes. Cheap parcels, cheap entry, enormous volume.

On 29 August 2025, the United States removed the exemption. Every shipment now attracts duty regardless of value, which raises the landed cost of exactly the parcels All-Link was flying. The prospectus does not hide the consequence. It states that the removal “materially and adversely impacted” the group’s performance through a decline in volumes for the TikTok Group. The number tells the story: TikTok went from about 98% of revenue in FY2024 to about 45% in FY2025. The company is listing into the aftermath of the event that made it.

The pivot the story now depends on

Management is not blind to any of this, and the FY2025 numbers already show the beginning of a pivot. A new customer, described only as a US-listed multinational technology company with over US$2 billion of annual profit, arrived and contributed 33.6% of FY2025 revenue. The Malaysian and Philippine arms, which were rounding errors a year earlier, together reached about 9.6% of revenue. The stated plan is to push into Vietnam and Thailand, buy the Vietnamese affiliate, and diversify away from both TikTok and, over time, the All-Link PRC referral channel.

It is the obvious strategy. Whether it is a moat is a different question, and honesty requires stating where the strategy is weaker. Swapping a 98% dependence on one customer for a 34% dependence on another is real progress, but it is still concentration. The Malaysian growth was bought, not built, which is a faster route but a more expensive and less certain one. And the deepest dependency, the referral relationship with a family-controlled entity, is not something the diversification plan removes so much as leans on, since the new customers are still being won inside a network the family assembled. A forwarder’s genuine edge is density and relationships in specific trade lanes, and All-Link does have a credible one, handling an estimated 12% of Vietnam-origin air cargo to the United States in 2025. The trouble is that its largest lane by far was the China-to-US e-commerce lane, and that lane is precisely the one policy has turned against.

The cross-border parcel question

Every sector has a cautionary tale, and All-Link’s is not a single failed company but a whole category. The China-to-US low-value parcel boom created a generation of logistics and e-commerce businesses whose unit economics quietly assumed the de minimis exemption would last. When the exemption went, the volume went with it, and the businesses built on top of it discovered that a regulatory subsidy is not the same as a competitive advantage. All-Link’s own industry report, prepared by Frost & Sullivan, acknowledges the shift, noting a sharp contraction in low-value direct-to-consumer parcels, partly offset by a move toward consolidated bulk freight.

What is genuinely different in All-Link’s favour is that it is small, nimble, profitable and debt-free, and that it saw the shift early enough to start diversifying before listing rather than after. What is not different is the structural lesson: a business whose scale came from a policy window should be valued as if that window can close, because in this case it already has. The honest verdict is that the pivot is plausible and underway, but unproven, and the burden of proof sits with the next two years of results, not with the FY2024 revenue peak.

What the market is asking you to pay

Now that the price is fixed, the question stops being abstract. At S$0.53, All-Link is valued at about S$80 million. Against FY2025 profit attributable to owners of US$6.3 million, roughly S$8.1 million at the prospectus reference rate, that is a trailing price-to-earnings multiple of about 9.9 times. The post-offering earnings-per-share the company itself discloses, US 4.17 cents, lands on the same 9.9 times, so the figure is internally consistent. Measured instead against the FY2024 peak, when owner profit was US$8.4 million, the multiple is about 7.4 times. In other words, the market is paying roughly ten times the earnings of a year in which those earnings had already fallen a quarter.

There is a second lens that matters for an asset-light, cash-rich company, and it cuts the other way. After the pre-IPO dividend and the fresh money raised, All-Link should sit on something like US$29 million of net cash and near-zero debt, against a market value of about US$62 million. Strip the cash out and the operating business is being valued at roughly US$33 million, or a little over five times its FY2025 owner earnings. That is a much less demanding number, and it is the honest way to see what you are paying for the franchise itself rather than for the bank balance that comes attached. The tension between those two figures, ten times on the headline and about five times net of cash, is the whole valuation debate in miniature: the cash is real and large, but it is the earnings power, not the cash, whose durability is in question.

On dividends, there is little for a new buyer to price yet. The US$8.0 million already declared went to the existing owners before listing, so new shareholders do not receive it. Going forward the board has stated an intention, though not a binding policy, to pay out at least 30% of profit attributable to shareholders for FY2026 through FY2028. Applied to last year’s profit, that would have come to roughly 1.6 Singapore cents a share, or about 3% at the offer price. Whether it comes to that again depends on a profit line that fell 25% in the year just reported, and on cash reaching the listed holding company itself, since dividends must be paid out of its own distributable profits rather than the group’s.

How that compares with the neighbours

A multiple means little without a comparison of similar size, since small companies trade at structurally lower multiples than large ones. Nine freight forwarders listed in Malaysia, Thailand and Vietnam sit within a third to four times All-Link’s S$80 million. Their median trailing multiple is 9.9 times. All-Link is being offered at 9.9 times. Against the companies it most resembles, it is priced almost exactly in line.

One name in that set breaks the pattern, and it is the one that matters most. AGX Group Berhad, All-Link’s own controlling shareholder, running substantially the same business in the same markets, trades at about 15.8 times. The subsidiary is being sold to the public roughly 40% cheaper than the parent that controls it. That gap is not the sector’s verdict, because the sector median is 9.9 times. It is a verdict on this company in particular.

Singapore itself offers little to measure against. The exchange has no listed pure freight forwarder, and the three groups that do carry forwarding businesses, Vibrant Group, GKE Corporation and Chasen Holdings, trade on 5.4 to 7.7 times earnings. But each owns its warehouses and plant, so what they price is asset-heavy logistics rather than forwarding.

On assets there is no such ambiguity. Price-to-book measures what a buyer pays against the accounting value of what a company owns, and All-Link is the most expensive name in the comparison by a wide margin: about 2.8 times book, after the pre-IPO dividend and the new proceeds, against a forwarder median just under 1.0. No other company in the set, the parent included at 2.0, reaches two times.

The two readings meet in the middle. An asset-light forwarder owns almost nothing, so its book is thin and its return on that book looks extraordinary for as long as the work keeps arriving: about 29% on post-listing equity in FY2025, against a peer median near 8%. That ought to command a premium to book, and it does. What it is not getting is any premium on earnings, which is the market’s way of saying it doubts the 29% survives. If the return holds, three times book will look cheap. If it drifts back toward the sector’s 8%, the buyer holds the premium with no earnings discount to cushion it.

The bull, the bear, and the honest answer

The bull thesis is simple.

• It is an asset-light, profitable, and cash flow generative company that started from scratch and generated US$74 million of revenue in two years, has no debt, has management with extensive local logistics experience, is already diversifying its customer base and geographically, and is going public with new money to fuel an ASEAN expansion into some of the fastest-growing airfreight markets in the world.

• It is trading at five times net of cash last year’s profits, which is not an ambitious valuation for a logistics company with growth potential. If the strategy succeeds, the small surprise may just be a growing pain.

The bear case is equally clear, and sits mostly in the ownership and dependency structure rather than the trading.

• The revenue engine is a related party the minority cannot control.

• The single biggest customer’s volumes have already halved on a policy change with no obvious reversal.

• Profitability is falling, not rising. Margins are thin and getting thinner.

• The controllers extracted US$8 million in dividends immediately before listing, kept three-quarters of the company, and floated only a sliver to the public, and

• the whole edifice of referrals rests on the family remaining in control, which is exactly what an eventual sell-down would erode.

• On the one measure where the peer comparison is unambiguous, the shares are being floated at roughly three times what comparable forwarders fetch for their book value, with no discount on earnings to offset it.

The honest answer is that both cases are true at once, and that the deciding question is not really about logistics. It is about whether you believe a business assembled around one family’s China relationships and one customer’s tariff-advantaged parcels can become a diversified, self-standing ASEAN forwarder now that the advantage is gone. The prospectus gives you the evidence for the attempt and, at last, the price of the ticket. What it cannot give you is the result. At close to ten times a falling earnings line, the market is asking investors to pay for a transition that has only just begun.

Data integrity notes

Items materially relevant to readers, including estimates, definitions and known limitations.

1. All company figures come from the offer documents. Financial data is drawn from the prospectus dated 28 July 2026 and the accompanying Product Highlights Sheet, covering audited results for the financial years ended 31 December 2023, 2024 and 2025 [1][2].

2. Currency conversions use the prospectus rate. The group reports in United States dollars while the offer is priced in Singapore dollars. Conversions use the prospectus reference rate of US$1.00 to S$1.2881 as at the Latest Practicable Date [1].

3. The valuation measures are our own calculations. Market capitalisation, the trailing price-to-earnings and price-to-book multiples, the post-listing net cash estimate and the illustrative dividend are calculated from disclosed figures at the S$0.53 offer price and the 151,037,900 shares in issue after the offering. Book value is struck after the pre-IPO dividend and the net proceeds [1][2].

4. Two concentration measures should not be read as one. The Major Customers table gives the combined share of customers that each contributed 5% or more of revenue, at 99.7%, 98.0% and 84.9% for FY2023 to FY2025. The risk factors give top-five customer concentration, at 99.7%, 99.8% and 89.9%. The series diverge because the fourth and fifth largest customers each fell below the 5% threshold in the later years [1].

5. Peer multiples are indicative. They rest on traded prices as at 10 July 2026 and will have moved, while All-Link’s rest on an offer price and audited figures. The comparison is limited to freight forwarders worth between a third and four times All-Link, since multiples are size-sensitive, and excludes loss-making and distorted-earnings names. Widening the size band would raise the earnings median from 9.9 to 11.0 times; the narrower and less flattering figure is the one used [4].

6. The three Singapore names are context, not comparables. Vibrant Group, GKE Corporation and Chasen Holdings each run freight forwarding alongside property, materials or relocation businesses and own their asset base, so they sit outside the medians [4].

7. The industry figures are from the commissioned report. Air-cargo corridor shares and market commentary come from the Frost & Sullivan report reproduced in the prospectus, not from independent verification [3].

8. No third-party research was used. No sell-side or analyst research was an input. The article draws no forward earnings estimate, valuation target or recommendation.

References

[1] All-Link Air & Sea Limited, “Prospectus dated 28 July 2026,” lodged with and registered by the Monetary Authority of Singapore (audited FY2023-FY2025 financial statements, offer terms, capitalisation, use of proceeds, major customers and major suppliers, interested person transactions, moratorium undertakings, dividends, risk factors). Primary source for all company figures.

[2] All-Link Air & Sea Limited, “Appendix 4 Product Highlights Sheet dated 28 July 2026.” Both documents are available via the SGX-ST website and the MAS OPERA portal.

[3] Frost & Sullivan (Singapore) Pte Ltd, “Independent Industry Report,” reproduced as Appendix G in the All-Link Air & Sea Limited prospectus (ASEAN air-cargo growth rates, corridor tonnage and market share, cross-border e-commerce commentary).

[4] Peer valuation data for listed ASEAN freight forwarders, from exchange filings and market data as at 10 July 2026. Median set: MPJ Logistics (SET MPJ), TASCO (Bursa 5140), Triple i Logistics (SET III), Sonic Interfreight (SET SONIC), FM Global Logistics (Bursa 7210), South Logistics (HOSE STG), AGX Group (Bursa 0299), Sino Logistics (SET SINO), WICE Logistics (SET WICE). Core forwarders outside the size band: Tri-Mode System (Bursa 0199), Transimex (HOSE TMS). Singapore-listed logistics groups shown for local context: Vibrant Group (SGX BIP), GKE Corporation (SGX 595), Chasen Holdings (SGX 5NV).

[5] United States executive action removing the de minimis exemption for imports valued under US$800, effective 29 August 2025, as described in the All-Link prospectus risk factors and industry report.

Important Disclaimers

This article is published for informational and educational purposes only. It does not constitute financial advice, a recommendation, or a solicitation to buy, sell or hold any securities. The author is not a licensed financial adviser under the Financial Advisers Act 2001 of Singapore and this content is exempt under Regulation 34 of the Financial Advisers Regulations as a generally available publication. Consult a licensed adviser before investing. Past performance is not indicative of future results. The author holds no position in the securities discussed.

If you have seen a specialist at Mount Elizabeth Novena, Gleneagles, Farrer Park or Mount Alvernia in the past two years, there is a fair chance that doctor now works, indirectly, for a company Temasek helped seed in 2022. In under four years Foundation Healthcare Holdings has bought control of established specialist practices across Singapore, and it is now asking the market to value the result at S$1.01 billion to S$1.20 billion: a price range of S$0.76 to S$0.92 a share, raising around S$242 million, with SGX Mainboard trading expected from 8 July 2026 [3].

The headline numbers are genuinely impressive. Revenue grew from S$112.4 million in FY2023 to S$231.2 million in FY2025. Group profit rose from S$7.3 million to S$41.2 million over the same two years. Among the key private specialist groups in Frost & Sullivan’s comparison, it is the largest by number of doctors and clinics, and the fastest growing by revenue from FY2024 to FY2025 [2]. Ten cornerstone investors, including the International Finance Corporation, Manulife, RBC, UBS and Lion Global, have committed S$118.2 million between them.

The number that matters most, though, is none of those. Of the S$41.2 million the group earned in FY2025, only S$14.0 million was attributable to shareholders of the parent company. The other S$27.2 million, two thirds of the total, was attributable to non-controlling shareholders, principally the minority owners of its part-owned specialist practices. How the company closes that gap, and what closing it costs, is the question the rest of this piece is about.

From a Temasek bet to Singapore’s largest specialist platform

Foundation Healthcare was incorporated in August 2022, but its founders had worked together far longer. CEO Liaw Yit Ming was a vice president at Khazanah Nasional, then ran strategy and M&A at IHH Healthcare, owner of the Parkway and Gleneagles hospitals. COO Dr Lee Hong Huei spent almost two decades in senior roles at Parkway Pantai. CCO Choy Shook Yee came through IHH and AIA. Liaw had co-founded Smarter Health, an insurtech in which Lee and Choy were also shareholders and which is now a wholly owned subsidiary. They know the Singapore private-hospital world from the inside.

The capital came from SeaTown Private Capital Master Fund, part of Seviora Holdings and ultimately Temasek-owned, which committed S$150 million of preference funding in 2022, completed in 2023. With that and a S$192.5 million debt facility from March 2023, the company moved fast: in FY2023 alone it bought effective 60% stakes in 23 specialist practices plus a medical centre for S$337.2 million cash, adding the Care IVF fertility clinic and the Orchard day-surgery centre. By 31 March 2026 it ran 108 specialists across 16 specialties, 74 clinics and four medical centres, including a new Novena day-surgery centre that management, citing Frost & Sullivan, calls the largest standalone facility of its kind in Singapore [2].

The structure across almost every acquisition was the same: buy 60%, leave 40% with the selling doctor. That single design choice is the key to reading the financials.

What the offer actually contains

The offer mixes new shares from the company with vendor shares sold by SeaTown and the founders, plus an over-allotment option (UBS is stabilising manager). The company’s net proceeds are earmarked, in order, for more clinic and medical-centre acquisitions in Singapore, for expansion into Malaysia and Hong Kong (the IFC’s cornerstone money is tagged to Malaysia), and for working capital. None goes to repaying debt.

The cornerstone tranche is worth pausing on. S$118.2 million across ten credible institutions is genuine institutional validation of the offer. One structural detail the marketing will not emphasise, though, is that the cornerstones carry no lock-up: the six-month lock-up binds the company, and longer moratoria bind SeaTown and the two founder-directors, but the institutions that anchored the book are free to sell from day one. That is not a prediction about the aftermarket, only a reminder that a cornerstone book signals confidence at the offer price, not a floor under it once trading begins.

The S$27 million that did not reach shareholders

Notice what is missing from the group’s reported profit. In FY2025, Foundation earned S$41.2 million after tax, but S$27.2 million of that, fully 66%, was attributable to non-controlling interests, principally the minority owners of the group’s part-owned operating companies, above all the 60%-owned specialist practices. Only S$14.0 million flowed to equity holders of the parent. Basic earnings were 2.13 cents per share. This is the honest starting point, and it is far less flattering than the group revenue line.

The prospectus addresses this with a step taken just before listing, the Share Swap: the company issues 477,101,524 new shares to 82 Swap Shareholders and 10 Employee Specialists to acquire the remaining interests in 35 specialist-practice companies and the Orchard medical-centre company, lifting its effective ownership to 100%. The stake bought in is generally 40%, except for the Orchard centre at 39.5%. After that, all of each practice's profit belongs to the listed group rather than leaking to non-controlling interests, and on a pro forma basis attributable profit jumps to S$48.8 million, or 4.08 cents per share. Pro forma simply means "as if": it restates the year as though the swap and all the year's acquisitions had been in place on 1 January 2025, rather than counting each clinic only from the date its deal closed. Think of totting up a full year's pay on a salary you only started in September. The prospectus calls this information illustrative and not necessarily indicative of future results, which is the right way to read it. Adjusted profit after tax, the company's preferred measure, which strips out acquisition and capital-raising costs, the FY2023 warrant charge, derivative fair-value movements, impairments and other company-defined one-offs, is S$51.4 million pro forma.

Both numbers are real. The swap genuinely completes before the shares trade. But the swap is not free, and the price is not paid in cash. It is paid in alignment, and in dilution.

The dilution is worth seeing as a bridge, because for this IPO the share count is almost as important as the income statement.

The arithmetic is striking. The swap shares alone, about 477 million, are roughly 37% of the post-listing company, issued to the selling Swap Shareholders and Employee Specialists. Assuming the Founder Warrant Shares are issued under the reported offer terms, SeaTown, on 88.6% before the offer, is diluted below half even before selling a single vendor share. The swap reduces the pre-swap shareholders' collective ownership to a little over half, before the primary IPO issuance dilutes it further. For new investors, that dilution is the price of turning the leaky 60/40 structure into one where every dollar of profit counts: the same trade-off as before, seen from the share count rather than the income statement. The exact primary, vendor and over-allotment splits, and SeaTown's final stake, stay blank until the final prospectus sets the price; the bridge also leaves out small pre-IPO award-share tranches [1].

There is a flip side to that dilution, and it cuts against the idea that the doctors are getting a rich deal. Those 477 million shares are worth S$363 million to S$439 million across the offer range, struck against the S$27.2 million the bought-in 40% earned in FY2025: an acquisition multiple of roughly 13 to 16 times. That is well below the 21 to 25 times the IPO asks new investors to pay for the company as a whole, so the swap is accretive. Absorbing the 40% lifts earnings per share from about 2.1 cents to about 3.6 cents before any new money is raised. The doctors are, in effect, bought in below the listing multiple, trading a higher private valuation for liquidity, a listed currency and continued pay, with the lock-ups and clawbacks attached. A like-for-like read has limits, since an acquired, locked-up minority would normally fetch less than a freely traded share, but the direction is clear: on these terms the swap favours the incoming shareholder more than the selling doctor.

The trade-off is also about incentives, though it is less binary than it first looks. Under the 60/40 model a surgeon retained a 40% equity interest in the clinic they ran. After the swap they hold shares in a roughly 1.3 billion-share group, with most of the Swap Shares (472 of the 477 million; the Orchard-centre shares are excluded) under moratoria and performance-linked release of varying lengths, backed by a clawback through the escrow agent (UOB Kay Hian) if targets are missed. Crucially, the doctors also keep being paid: the prospectus says specialists receive a base salary and/or a variable component tied to the financial performance of the specialist clinic group in which they practise, with the restricted shares layered on top. So the real question is narrower than "ownership versus shares": does base-plus-clinic-performance pay, together with locked equity in the wider group, preserve the same owner-operator intensity as a direct 40% stake in one's own practice? It is the valuation case, not the pro forma accounting, that assumes it does, through the lock-up years.

The financial scoreboard

Set the ownership question aside for a moment, because the underlying business is clearly growing and clearly profitable at the operating level.

Revenue compounded at roughly 43% a year over two years, mostly from acquisitions rather than organic growth, and the pace is slowing (up 77.0% in FY2024, 16.2% in FY2025). Adjusted EBITDA margins held in a tight 37% to 40% band, high for healthcare services and a function of a surgical, procedure-heavy mix. Company-defined adjusted return on equity (Adjusted PAT over total equity) was 18.9%, or 22.0% pro forma, and free cash flow conversion ran at 76.5% of adjusted EBITDA. The business throws off cash.

The caution sits one layer down. For the three months to 31 March 2026 the company said preliminary trends pointed to higher revenue and slightly higher Adjusted EBITDA, but lower profit and Adjusted PAT than a year earlier. The disclosed drivers: a third of its 108 specialists (34) are now “Emerging Specialists” still building their books; headquarters headcount rose from 43 to 71 for listed life; the new Novena centre is ramping; and Orchard closed in March for refurbishment. Management attributes much of the pressure to investment and ramp-up costs, though the preliminary data is not enough to rule out other operating effects. The ramp does have a rough timeline. The prospectus classifies a doctor as “Established” only after five years in private practice, and a defined cohort of Emerging Specialists employed at least twelve months generated about S$1.3 million each, against the S$2.7 million a comparable Established Specialist averaged. That points to a multi-year development period, though it does not prove revenue rises evenly or takes the full five years; either way the recovery runs over years, not a couple of quarters, which is why a doctor-heavy year depresses margins before lifting them. It also means the pro forma S$51.4 million is an everything-acquired, full-year snapshot, not a run rate proven quarter after quarter.

The cash flow and the debt

This is where the model asks for vigilance. The growth was bought, and it was bought substantially with borrowed money. At the end of FY2025, borrowings excluding lease liabilities were S$302.0 million, against S$85.3 million of cash and equivalents plus S$11.1 million of restricted cash. On the pro forma balance sheet, total borrowings including leases were S$348.0 million and cash and bank balances were S$71.6 million, implying simple net debt of about S$276.4 million, or 2.8 times pro forma Adjusted EBITDA (S$99.1 million); this is our own calculation, not the banking covenant measure. Finance expense alone was S$17.8 million in FY2025, a meaningful claim on operating cash flow. The senior facility carries interest at SORA (Singapore’s benchmark interest rate) plus a margin of 2.25% to 3.00%, with covenants that include a maximum total leverage ratio of 4.0 times and an interest-cover floor of 1.75 to 2.0 times.

Two features deserve attention. First, the facility blocks the subsidiaries from paying dividends up to the parent if that would breach the covenants, which is why the prospectus warns the company “may be constrained from paying dividends”: the cash is earned in the subsidiaries, but the listed shell sits above the covenant gate. Second, the interest-rate swaps hedging S$247 million at about 5.5% are not designated as hedges, so their mark-to-market swings run through the income statement as the “fair value loss on derivatives”, the source of those line items, not any option owed to the doctors.

The balance sheet is also unusually intangible. Goodwill represented 70.6% of total assets at the end of FY2025. That is the natural arithmetic of a roll-up that pays for established practices, and it leaves tangible asset backing thin. The pre-offering pro forma net asset value (the accounting book value per share, before the primary cash from the offer comes in) was just S$0.18; the post-offering figure will be disclosed in the final prospectus once pricing and the number of new shares are fixed. Either way, the value here is the earnings stream and the network, not the assets on the page.

The controller, the board, and negative tangible net worth

Governance is better than the typical new Singapore listing in some respects, and worth watching in others. The board is genuinely independent in form: an independent non-executive chairman (Stephen Lim), four of six directors independent, and an Audit and Risk Committee chaired by Max Loh, a former Ernst & Young Singapore managing partner. Despite owning 88.6% before the offer, SeaTown places no nominee director on the board, and Temasek’s stated policy is not to direct its portfolio companies’ operations. Executive cash pay is modest (the chief executive in the S$500,000 to S$750,000 band), and the disclosed related-party dealings are small and on ordinary commercial terms (Singtel telecoms, a SeaTown-linked medical-supplies distributor, each under S$200,000 a year). No clinics are leased from insiders.

Two things deserve a second look. The first is that the technology effort behind the platform story was bought in from related parties. Smarter Health, the insurtech Liaw co-founded, was acquired into the group in exchange for shares; the prospectus lists 27 sellers, among them Liaw, Lee and entities associated with them. It says the deal was struck on the same terms as with an unrelated party, but the founders and their associates sat on both sides of it.

The second is the balance sheet, and it is worth slowing down for. Most of what Foundation “owns” is goodwill: the premium it paid to buy profitable clinics over and above the value of their physical assets like equipment and cash. Strip that goodwill out and the company’s tangible net worth is negative, roughly S$206 million in the red at the end of FY2025. That has an unusual side-effect for small shareholders. Normally, when a listed company wants to do a sizeable deal with one of its own insiders (its controlling owner, a director, or a related party), that deal must be put to a vote of the other shareholders once it crosses 5% of the company’s tangible net worth, a built-in check against insiders extracting value. With that net worth below zero, the percentage cannot be calculated, so the SGX has let Foundation measure the limit against its market value (around S$1.1 billion) instead, until it reports its FY2026 results. That keeps the rule working, but it raises the dollar value of the 5% shareholder-approval threshold, so larger insider deals can clear on audit-committee review alone; transactions at or above that threshold still go to a shareholder vote [1].

A moat that depends on the people it just bought out

Foundation’s competitive case is real. Scale gives it buying power on drugs, supplies and payment processing, and a centralised patient funnel through its Health Connective Programme and the AVA technology platform that smaller visiting-specialist groups cannot match. Employing its doctors full-time, rather than the visiting or sessional model used by certain peer platforms, allows tighter coordination and lets it capture facility and diagnostic fees at its own medical centres. Its pro forma 18.2% net margin comfortably beats Frost & Sullivan’s anonymised peers, whose margins ran from 9.3% down to 5.2% [2].

The payor relationships are the most defensible layer. The April 2025 Great Eastern partnership and the empanelment of more than 97% of its specialists (excluding anaesthesiologists and radiologists) with two or more insurers and third-party administrators make Foundation a preferred network just as medical costs climb. The widely cited 16.9% inflation figure for 2026 (15.5% for 2025) [2][4] needs care: it traces to WTW’s Global Medical Trends survey, the most aggressive of the consultancy forecasts (Aon put 2026 at 13%, Mercer Marsh at 14%), and measures an insurer “medical trend” of utilisation and case-mix shifts, not pure prices; the Ministry of Health puts the actual Healthcare Consumer Price Index nearer 3% in 2025 [5]. Either way, insurers are squeezed and pushing toward cost containment and day-surgery settings, so a platform offering predictable pricing and cheaper outpatient procedures has a structural reason to exist.

That same pressure cuts the other way, though, and this is where the payor layer is less of a moat than it looks. To contain costs, insurers are narrowing their networks: Prudential and Great Eastern now name partner-hospital panels, and in 2025 Great Eastern briefly suspended pre-authorisation at the two Mount Elizabeth hospitals after finding bills there ran 20% to 30% above comparable facilities [5]. Foundation’s clinic footprint is heavily concentrated in exactly those higher-cost hospitals: 22 clinics at Mount Elizabeth Novena and 16 at Mount Elizabeth Orchard. The relationship that the prospectus frames as a moat is the same lever insurers are using to steer patients toward cheaper venues. It can be an advantage and an exposure at once.

One feature of the revenue base is worth being careful about. The prospectus emphasises Singapore-based channels, a funnel of local residents, insurer and third-party-administrator empanelment and GP referrals, and it contemplates patients paying providers directly and then seeking reimbursement [1]. What it does not disclose is the split of revenue by patient nationality, by insurer versus self-pay, or any foreign-patient share. So the business is clearly Singapore-centric, but the absence of any medical-tourism discussion is not evidence that there are no foreign or cash-paying patients. Unlike the hospital majors, Foundation does not market itself on foreign-patient inflows; how much that insulates it, or limits it, when insurers tighten panels is not something the filing lets us quantify.

Where the moat is weaker is the same place the earnings come from. A specialist group is, ultimately, its specialists, and the average doctor here is around 52 years old with 25 years of experience. The relationships, the referrals and the reputations belong to individuals. The Share Swap and its moratoria are explicitly designed to bind those individuals to the platform, which is an admission that, without contractual lock-ins, they could walk. A moat that has to be written into an escrow agreement is a moat under construction, not one that has weathered a cycle.

The roll-up question the prospectus does not ask

There is a precedent for buying up doctors’ practices at scale on debt and listing the result on a growth multiple. In the United States in the 1990s, physician practice management companies such as MedPartners, PhyCor and PhyMatrix did exactly that, were valued as compounders, then collapsed when acquired-practice productivity faded and the bought-in doctors’ incentives drifted from shareholders’. The lesson was not that the model cannot work, since IHH and others built durable specialist businesses, but that the moment of maximum optimism is usually the listing, while the acquisition machine is still running and the incentives are fresh. Foundation is genuinely different in important ways: a single, highly regulated, high-margin market, Temasek governance, covenant discipline, real margins and cash today, and a moratorium-with-clawback more thoughtful than a simple earnout.

The closer-to-home precedent is more pointed. The previous generation of SGX-listed medical-group roll-ups has almost all left the exchange, usually cheaply: Singapore Medical Group taken private in 2022 [8], Healthway Medical delisted in 2023 [9], TalkMed privatised at S$0.456 (about S$606 million) in 2025 [10], and Singapore Paincare’s buyout collapsing at the end of 2025, leaving a loss-making shell [11]. Singapore’s public market has not historically held a premium multiple on a listed specialist roll-up; the usual end-state has been a take-private at a modest price. Neither the 584-page prospectus nor its Frost & Sullivan market-research appendix mentions any of this. Investors should supply the history themselves.

What the market is asking you to pay

Here is the valuation stated plainly, and it depends entirely on which earnings number you accept. Across the S$0.76 to S$0.92 offer range, the company is valued at

Read more

The company behind those desks, though, has drawn far less scrutiny than the product it sells. On 22 May 2026, JustCo Holdings Limited lists on the SGX Mainboard, and the offer document gives us the first proper look at the numbers. The headline tension is visible from the first page. JustCo is raising S$100 million in gross proceeds. In its most recent financial year it earned a net profit of US$2.7 million. A raise of that size against a profit of that size implies the market is being asked to pay a very full price, and it invites the comparison every flexible-office IPO now has to answer: is this the next WeWork story, or something sturdier? We read the prospectus to find out.

From JustOffice to JustCo

JustCo began in 2011, not 2018. The 2018 date on the prospectus cover is when the current holding company was incorporated; the business is older. Founder Kong Wan Sing started it with two co-founders as “JustOffice”, a single 3,132 square foot space in Samsung Hub in the heart of the Singapore CBD. The bet was simple: office supply was tight, rents were rising, and the way companies wanted to use space was changing faster than traditional leases allowed.

Growth came in stages. Between 2017 and 2019, equity from Sansiri, GIC and Frasers Property turned a Singapore operator into a regional one, and JustCo expanded into Australia, Taiwan, Thailand, South Korea and Japan at a pace of roughly one new centre every three weeks. The pandemic was the first real test: occupancy fell to just above 60% at the worst of it. The company’s response is worth noting, because it is the opposite of the WeWork playbook. JustCo exited mainland China and Indonesia rather than defend every market. Today it operates 54 centres across 12 cities, with around 37,500 workstations, and it sells under three brands: The Collective at the luxury end, JustCo as the core premium product, and the boring office as an essentials line.

What the offer actually contains

The offer is 32,092,000 new shares at S$0.94 each, with a further 5,319,000 vendor shares available through an over-allotment option. Sitting alongside it is a much larger cornerstone tranche of 74,291,000 shares. Together the new shares raise S$100.0 million gross and S$92.2 million net to the company. After listing, JustCo will have 489,235,758 shares in issue, which at the offer price puts the market capitalisation just under S$460 million.

The register is heavily anchored. GIC holds 22.74% after listing, Frasers Property and the Charoen Sirivadhanabhakdi interests hold 17.63%, and founder Kong Wan Sing’s family vehicle holds 17.79%. The cornerstone investors, a group that includes JPMorgan Asset Management, Fullerton, Maybank Asset Management, Avanda and Amova, take another 15.19%. Hsieh Fu Hua, a familiar name in Singapore capital markets, chairs the board as lead independent director.

The money has a clear job. S$81.7 million of the gross proceeds is earmarked for expansion, fit-outs and capital expenditure, with S$56.8 million of that tied to 20 committed new centres. Another S$10.0 million is for working capital, and S$8.3 million covers the fees of the offering. In total, JustCo plans to open around 28 new centres in 2026.

A small float by design, not by accident

Notice what is missing from those numbers: any meaningful sale of existing shares. The 5.3 million over-allotment is just over 1% of the company, and it comes from the Kong family’s holding vehicle. GIC, Frasers, the Kong family and Pinetree are not using this listing to cash out. That leaves an unusually small free float of about 6.6%, rising to 7.6% if the over-allotment is fully taken up. A typical SGX Mainboard listing sells 15% to 25% of the company; JustCo sold the minimum needed to raise the capital it wanted, and not a share more.

Three things follow. The deal raised what was needed and no more, which is a capital-discipline signal in a market where IPOs are often sized to deliver an exit rather than to fund growth. The existing register is genuinely committed: GIC and Frasers came in between 2017 and 2019 and are choosing to mark their investment publicly rather than monetise it. And the tradable float will grow mechanically as lock-ups unwind. The standard SGX six-month moratorium releases the cornerstone tranche around the fourth quarter of 2026, taking effective float past 21%, with the controlling-shareholder shares coming off lock-up at twelve months. The post-listing share price in those early months will therefore partly reflect scarcity rather than fundamentals, which flatters it now and creates an overhang later, when supply normalises even if nothing about the business has changed.

The point underneath all of this is that the tight float is a design choice, not a forced outcome. JustCo could have sold more shares and produced a normal float, and it chose not to. That signals confidence in being able to come back to market later, and a reluctance to dilute further at what the existing register evidently sees as a still-early price.

The financial scoreboard

Revenue has compounded steadily, from US$113.8 million in FY2023 to US$128.2 million in FY2024 to US$144.2 million in FY2025, a little under 13% a year. The profit line is the part that needs care. JustCo lost US$12.5 million after tax in FY2023 and US$10.1 million in FY2024 before reporting a US$2.7 million profit in FY2025. That maiden profit, though, leans on a one-off. FY2025 other income included a US$3.7 million non-cash fair value gain on the remeasurement of JustCo’s pre-existing stake in its Japan operations, recognised when it bought out the rest of that business. Strip that gain out and FY2025 would have been a pre-tax loss of roughly US$1.8 million. The turn to profit is real on the reported line, but the underlying business has not quite crossed into the black yet.

The more useful trend is Cash EBITDA, the company’s measure of cash generated at centre level after actual rent is paid. It rose from US$3.4 million to US$6.2 million to US$13.5 million across the three years, and the margin widened from 3.0% to 9.4%. Occupancy improved from 78% to 84%, and the renewal rate climbed from 64.7% to 72.0%. The operating story is one of a business getting steadily more efficient as its centres mature.

The cash flow puzzle

One number in the scoreboard looks too good, and it is worth slowing down on. JustCo generated US$101.2 million of net cash from operating activities in FY2025. That is more than seven times its FY2025 Cash EBITDA of US$13.5 million, and around thirty-seven times its reported net profit. It is not a sign of a cash machine hiding inside the income statement. It is an accounting effect.

Under the lease accounting standard that applies here, the rent JustCo pays on its centres does not all run through operating cash flow. The interest portion does, but the much larger principal portion is recorded as a financing outflow. In FY2025 net cash used in financing was US$77.1 million, most of it lease repayments. So the US$101 million operating figure is, in plain terms, cash generated before paying most of the rent. The honest measure of what the business kept is further down: after rent, after capital expenditure, and after everything else, cash on the balance sheet rose by US$11.2 million. JustCo is cash generative. It is generative in the low tens of millions, not the hundred-million range the operating line first suggests.

A moat that is strongest when you need it least

A moat is whatever stops a competitor from copying a business and taking its customers. JustCo has one. The question for this offer is not whether it exists, but how well it holds when conditions turn, because the whole investment case rests on occupancy staying high and new centres filling up on schedule.

Start with what is genuinely defensible. JustCo is neither the biggest flexible-office operator in Asia nor the oldest. It competes against IWG, the listed owner of Regus and Spaces that has run this business since 1989, against the long-established premium operators The Executive Centre and Servcorp, and against a restructured WeWork. What JustCo has built instead is density in a handful of cities. The market study commissioned for the prospectus puts its share of flexible workspace stock at around 16% in Singapore, a comparable level in Bangkok, and higher in Taipei [1]. In those cities, a corporate real estate team drawing up a shortlist of options will almost always include JustCo. Being the default option in your core markets is a real advantage, and it is the strongest layer of the moat.

But notice what that advantage depends on. A network of workspace centres is only valuable to a member when the centres are full and active. This is what economists call a network effect: the product gets better for each customer as more customers use it. In a good year, full centres generate referrals, landlords compete to host JustCo, and the density looks like a fortress. In a bad year, the same network is a row of half-empty floors with the rent still due on every one of them. The moat, in other words, is pro-cyclical. It reinforces itself when times are good and erodes when times are hard. That is the opposite of what an investor wants from a moat, because the entire point of a moat is to protect a business when the cycle turns against it. JustCo’s is strongest exactly when it is needed least.

The management-contract model softens this, but only on one side. When a landlord funds the fit-out and shares the revenue, a weak year hurts JustCo less on those centres, because the pain is shared with the building owner. That protects the balance sheet. It does not make a single member more loyal, so it is not a demand-side moat.

And the demand side is where the moat is thinnest. JustCo’s members stay an average of about 15 months, so the moat has to be re-won, customer by customer, on a rolling basis: roughly 28% of the workstations due for renewal in 2025 were not renewed. The product itself is substitutable, because one operator’s private office differs from another’s mainly on location, price and fit-out quality, all of which a well-funded rival can match. Landlords who have watched the model work can choose to run flexible space themselves. And the city-level density, real as it is, sits inside a small niche. Flexible space is only about 6% of all office space in the region, so a 16% share of Singapore’s flexible market works out closer to 1% of the city’s total office stock. JustCo is a meaningful operator in a young, still-small slice of the property market, not an entrenched one in a large and mature market.

The WeWork question

The comparison is unavoidable, so we will take it head on. JustCo itself seems to know it: a sign in its centres reads “Let’s Make Work Better”, and the wordplay against the name of its largest cautionary tale is almost certainly deliberate. JustCo’s prospectus does not mention WeWork in its risk factors, but the structural feature that broke WeWork is present here too. JustCo signs leases with initial terms generally running three to ten years. Its members sign up for an average of about 15 months. That gap between long, fixed commitments on one side and short, cancellable revenue on the other is the central vulnerability of the leased-office model. It is why, at end-FY2025, JustCo carried US$402.2 million of lease liabilities against just US$40.4 million of total equity. When occupancy holds, this works. When occupancy falls, the rent does not.

What is genuinely different is almost everything else. WeWork at its 2019 IPO attempt carried around US$47 billion of lease commitments against roughly US$4 billion of rental income, was burning cash at scale, and had governance problems that became their own story. JustCo is a fraction of that size, grew at a measured pace, walked away from China and Indonesia rather than chase every flag on the map, and runs about three-quarters of its mature space under management contracts in which the landlord funds the fit-out and shares the risk. It is cash positive after everything. Its register is GIC and Frasers, not a single dominant venture backer. The honest answer is that JustCo is not WeWork. But it shares WeWork’s core structural risk, and an investor buying the IPO is buying that risk at a price that leaves little room for the occupancy cycle to disappoint.

What the market is asking you to pay

At S$0.94, the post-listing market capitalisation is just under S$460 million. Against FY2025 net profit after tax of US$2.7 million, about S$3.5 million at the rate the prospectus uses, that is a trailing price-to-earnings multiple of roughly 130 times. And because the maiden profit rests on a one-off gain, the underlying business produced no profit to multiply at all. On the company’s preferred measure, the offer values JustCo at around 27 times its FY2025 Cash EBITDA of US$13.5 million. There is no dividend policy, and none has ever been paid.

We are deliberately not putting a forward number on this article. Whether 130 times trailing earnings is the wrong price or simply an early price depends entirely on what FY2026 and FY2027 look like as 28 new centres open and season, and that forward build is a separate piece of work. What we will say plainly is what the offer price is, and what it is not. It is not a value entry point. It is a growth price, and it asks the buyer to underwrite the next two years of expansion going broadly to plan.

The bull, the bear, and the honest answer

The bull case is that JustCo is a real franchise at an inflection. Occupancy and renewal rates are both rising, the Cash EBITDA margin has tripled in three years, and the management-contract model lets the company keep growing without putting every fit-out dollar on its own balance sheet. The flexible-office market across Asia Pacific is still lightly penetrated relative to mature markets like central London, which leaves room to grow into [1]. And the quality of the register matters: GIC, Frasers and a serious cornerstone book do not anchor a business they expect to unravel.

The bear case is that the price gives you no margin for error. The maiden profit is flattered by a one-off, the structural lease-versus-membership mismatch is real and large, the free float is thin enough to make the early share price as much about scarcity as about fundamentals, there is no dividend to wait on, and the raise itself adds 28 centres of fresh lease liability and the associated drag before those centres mature. Every one of the bull points depends on the occupancy cycle staying friendly, and the moat that is supposed to hold occupancy up is, as we have seen, weakest precisely when the cycle turns against it.

The honest answer is that both cases are true at once, and the IPO price is what forces the choice. JustCo has built something durable enough that GIC and Frasers want to own it, and fragile enough, structurally, that the WeWork question is fair to ask. At nearly S$460 million on a business that has not yet made an underlying profit, the market is being asked to pay for the growth before it arrives. Whether that is a price worth paying is the question the offer puts to each investor, and it is not one we will answer for them.

Notes on data integrity

All financial figures in this article are drawn from the JustCo Holdings Limited Prospectus and the accompanying Product Highlights Sheet, both dated 15 May 2026. JustCo reports in US dollars; the offer is priced in Singapore dollars. Where we convert between the two, we use the rates the prospectus itself uses: approximately S$1.30 to US$1.00 for the FY2025 income statement, and S$1.2784 to US$1.00 as at the prospectus’s Latest Practicable Date. The trailing price-to-earnings multiple, the price-to-Cash EBITDA multiple, the post-listing market capitalisation and the underlying pre-tax loss excluding the Japan fair value gain are our own calculations from disclosed figures. “Cash EBITDA” is the company’s defined measure and is not a standard accounting metric; we use it as the company presents it. Flexible-office market penetration data is from the CBRE Independent Market Research Report commissioned for and reproduced in the prospectus. This is a focused first-look analysis of the offer, not a full research initiation, and it does not attempt a forward earnings estimate or a valuation target.

References

[1] CBRE Pte Ltd, “Market Due Diligence Report on Flexible Working Sector in Asia Pacific”, Independent Market Research Report reproduced as Appendix C in the JustCo Holdings Limited Prospectus dated 15 May 2026.

[2] JustCo Holdings Limited, “Prospectus dated 15 May 2026” and “Appendix 3 Product Highlights Sheet dated 15 May 2026”, lodged with and registered by the Monetary Authority of Singapore. Available via the SGX-ST website and the MAS OPERA portal.

[3] WeWork: comparative figures on its withdrawn September 2019 initial public offering and its lease commitments are drawn from contemporaneous public reporting; WeWork subsequently filed for Chapter 11 bankruptcy protection in November 2023.

IMPORTANT DISCLAIMERS

This article is published for informational and educational purposes only. It does not constitute financial or investment advice, a recommendation, or a solicitation to buy, sell, or hold any securities. The author is not a licensed financial adviser under the Financial Advisers Act 2001 of Singapore. This content is exempt from the requirements of the Singapore Financial Advisers Act pursuant to Regulation 34 of the Financial Advisers Regulations, as it is published in a generally available publication. This publication does not take into account the specific investment objectives, financial situation, or particular needs of any individual. Before making any investment decision, readers should consult a licensed financial or investment adviser in their relevant jurisdiction. Past performance is not indicative of future results.

No Warranty: While the data and analysis have been prepared in good faith from public sources believed to be reliable, no representation or warranty, express or implied, is made as to the accuracy, completeness, or timeliness of the information. The author accepts no liability for any loss arising from the use of this material.

Disclosure: The author may or may not hold positions in the securities discussed. No compensation has been received from any company mentioned in this article.